Navigation Links
Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
Date:11/5/2007

BRISBANE, Australia, Nov. 5 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced additional data from the Phase 2 liver cancer study of PI-88 completed earlier this year. This data was presented at the 58th Annual Meeting of the American Association for the Study of Liver Diseases in Boston, USA(1).

As the Phase 2 trial's study period covered 48 weeks from curative surgery, the data analysis described in this presentation was performed to evaluate the treatment's impact when patients with a low risk of experiencing a liver cancer recurrence within twelve months are removed from the analysis population. Patients were removed from the patient population if, based on published prognostic factors, they were considered likely to complete the 12 months of the study without recurrence.

The resultant analysis of those patients who had a high risk of recurrence in the 12-month period shows that PI-88 at least doubled the time to disease recurrence calculated at the 60th percentile (p=0.0107) (control (n=33): 24 weeks versus 160mg PI-88 (n=36): 48 weeks). This compares to a 76% improvement at the 70th percentile (p=0.0867) if all patients are included, as reported earlier this year.

Dr. James Garner, Progen's Vice President of Clinical and Medical Affairs, commented: "We know that around 50% of untreated patients are likely to experience disease recurrence within 12-15 months after they have had curative liver cancer resection. Given our Phase 2 study only assessed the recurrence of disease up to 12 months after surgery; this implies that approximately half of the study population were unable to provide information about the efficacy of the drug. When you remove from the analysis patients unlikely to recur in the study time frame, the treatment effect of PI-88 as measured in the Phase 2 study is more clearly demonstrated."

Dr. Garner further commented: "These data further expand our confidence that ou
'/>"/>

SOURCE Progen Pharmaceuticals Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Progen Pharmaceuticals Announces Fiscal 2007 Financial Results
3. Progen Announces PI-88 Phase 2 Lung Cancer Results
4. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
9. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
10. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
11. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... , April 28, 2015  Spark Therapeutics, ... Inc. announced today that they have entered into ... rights to license Clearside,s microinjector technology to deliver ... Under the agreement, the companies will explore the ... viral vectors to the choroid and the retina ...
(Date:4/28/2015)... 2015  Ascendis Pharma A/S (Nasdaq: ... that applies its TransCon technology to address ... its Phase 1 single ascending dose study ... plasma treprostinil levels in-line with expectations.  However, ... the criteria defined in the target product ...
(Date:4/28/2015)... , April 28, 2015  Nevro Corp. (NYSE: ... developed and commercialized an innovative, evidence-based neuromodulation platform for ... will release financial results for the first quarter of ... Company management will host a conference call beginning at ... Monday, May 11, 2015. Individuals interested ...
Breaking Medicine Technology:Spark Therapeutics and Clearside Biomedical Announce Exclusive Option to License Technology for Potentially Differentiated Delivery of Gene Therapy to the Eye 2Spark Therapeutics and Clearside Biomedical Announce Exclusive Option to License Technology for Potentially Differentiated Delivery of Gene Therapy to the Eye 3Spark Therapeutics and Clearside Biomedical Announce Exclusive Option to License Technology for Potentially Differentiated Delivery of Gene Therapy to the Eye 4Ascendis Pharma A/S Announces Results of Phase 1 Study of TransCon Treprostinil 2Ascendis Pharma A/S Announces Results of Phase 1 Study of TransCon Treprostinil 3Ascendis Pharma A/S Announces Results of Phase 1 Study of TransCon Treprostinil 4
... IsZo Capital Management LP, one of the largest minority shareholders ... ), announced today that it delivered the following letter to ... immediately from the agenda for the upcoming annual shareholders, meeting ... 2011 Board of Directors of Taro Pharmaceutical Industries ...
...  GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biopharmaceutical firm ... Immunodeficiency Virus (HIV) infections, announced that the first patient ... for the Company,s HIV/AIDS therapeutic vaccine.  This is the ... of persons who are HIV infected. The ...
Cached Medicine Technology:IzSo Capital Writes to Taro Pharmaceutical Board Demanding that Liability Protection Management Proposals be Removed Immediately from Agenda for Annual Shareholders' Meeting 2IzSo Capital Writes to Taro Pharmaceutical Board Demanding that Liability Protection Management Proposals be Removed Immediately from Agenda for Annual Shareholders' Meeting 3IzSo Capital Writes to Taro Pharmaceutical Board Demanding that Liability Protection Management Proposals be Removed Immediately from Agenda for Annual Shareholders' Meeting 4IzSo Capital Writes to Taro Pharmaceutical Board Demanding that Liability Protection Management Proposals be Removed Immediately from Agenda for Annual Shareholders' Meeting 5GeoVax Labs' First Patient Inoculated in Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine 2GeoVax Labs' First Patient Inoculated in Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine 3
(Date:4/28/2015)... Aurora, IL (PRWEB) April 28, 2015 ... and subsidiary of Briggs and Stratton, raised nearly $12,000 ... campaign that began in October 2014. MWE announced the ... to raise funds and awareness for wounded service members ... national nonprofit dedicated to restoring a sense of self, ...
(Date:4/28/2015)... VA (PRWEB) April 28, 2015 Sentara ... to securely share electronic patient health information across the ... and outpatient facilities in Hampton Roads and northern Virginia ... early adopters of a nationwide effort to improve care ... Roads and northern Virginia have one of the largest ...
(Date:4/28/2015)... Allied Anesthesia physicians are embracing the ... and is swiftly gaining ground across the country. , ... the experience more enjoyable and memorable for the mother ... process between mother and baby. , “We’re the hand ... Allied. , Maya and other Allied anesthesiologists have been ...
(Date:4/28/2015)... 2015 HomeTown Health, LLC held its ... at the Riverside Marriott in Savannah, Georgia with leading ... expertise and best practices required to survive the effects ... this conference was outstanding, and offers unparalleled value in ... sensitive and pressing needs of our hospitals.” said HomeTown ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 The Lymphoma ... devoted exclusively to funding innovative lymphoma research and serving ... programs, outreach initiatives and patient services – will once ... in Scarsdale, New York to host its Annual Golf ... will take place on May 18, 2015. , ...
Breaking Medicine News(10 mins):Health News:Midwest Engine Exceeds Donation Goal for the Second Year to Hope For The Warriors 2Health News:Sentara Healthcare Begins Sharing Electronic Patient Data with Department of Defense 2Health News:Allied Anesthesia Physicians Promote Gentle C-sections 2Health News:HomeTown Health Convenes Meeting of Leading Rural Health Experts in Savannah to Share Solutions for Survival at 15th Annual Spring Conference 2Health News:HomeTown Health Convenes Meeting of Leading Rural Health Experts in Savannah to Share Solutions for Survival at 15th Annual Spring Conference 3Health News:Lymphoma Research Foundation Returns to Prestigious Quaker Ridge Golf Club in Scarsdale, NY for Annual Golf Invitational 2
... 2, 2012 Combination drug therapy may be needed to ... by the Translational Genomics Research Institute (TGen) and Van Andel ... JAK2 Independent of Key Oncogenic Driver Mutation in Non-Small Cell ... the Public Library of Science (PLoS) ONE . ...
... Feb. 2 (HealthDay News) -- The sale of pet turtles ... the small reptiles are still available and continue to infect ... of the health danger, pet turtles are inappropriate pets in ... pregnant women, seniors and those with weak immune systems, according ...
... the most distinctive signs of the development of Alzheimer,s ... protein that neuroscientists call tau. In normal brains, tau ... In the cells of Alzheimer,s brains, by contrast, tau ... These tangles are considered a hallmark of the disease, ...
... Different kinds of lung cancer behave in different ways, ... University of Colorado Cancer Center study published in ... Society, different subgroups of non-small cell lung cancer (NSCLC) ... The study looked at 209 patients diagnosed with ...
... reason the prognosis for metastatic colon cancer has gone from ... Unfortunately, the drug can also carry with it debilitating neurological ... and needles in fingers and toes and can leave patients ... don,t receive the necessary dose to try to keep their ...
... -- A warning to certain types as those Super Bowl ... are more likely to eat too much in social situations, ... pressure to eat when they believe that their eating will ... Exline, a psychologist at Case Western Reserve University, said in ...
Cached Medicine News:Health News:Combination drug therapy urged to battle lung cancer 2Health News:Pet Turtles Carry Salmonella Dangers, CDC Warns 2Health News:Untangling the mysteries of Alzheimer's 2Health News:New research confirms need for lung cancer testing 2Health News:Balancing oxaliplatin dose with neurological side effects in metastatic colon cancer 2Health News:'People Pleasers' More Prone to Overeating: Study 2
... 220XiIII quickly prints labels up ... 10 ips. It is ideal ... as printing chemical drum labels, ... industry labels, banner-sized labels and ...
... Verification System, is used by hospitals ... the specific unit(s) of blood that ... It has the additional benefit of ... institution's policy and procedure for blood ...
... This system helps ensure a safe care environment ... down to the unit dose level. The automated ... track the location and handling of all items, ... eye preparations and more. This saves valuable time ...
... ensures your patients are receiving the proper ... uses the AutoPPI™ barcoded wristband to positively ... transfusion. SafeTx checks that the correct blood ... bedside paperwork and associated transcription errors. In ...
Medicine Products: